- Home
- Applications
- human natural vascular scaffolding clinical trial
Human Natural Vascular Scaffolding Clinical Trial Product Applications
3 applications found
Health Canada recently released “Proposed Regulations Amending the Cannabis Regulations (new classes of cannabis) and Proposed Order Amending Schedules 3 and 4 to the Cannabis Act”. These proposed changes introduce three new classes of cannabis products: edibles, concentrates and topicals. The introduction of these new classes may present an opportunity for the Company to bring combination products to the market as an adult-use edible cannabis product. It is proposed that only approved food ingredients ...
ByCanaQuest Medical Corp. based in Mississauga, ONTARIO (CANADA)
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...
ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)